Kena A. Swanson

33.0k total citations · 5 hit papers
40 papers, 2.0k citations indexed

About

Kena A. Swanson is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kena A. Swanson has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 21 papers in Infectious Diseases and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kena A. Swanson's work include Respiratory viral infections research (22 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Viral gastroenteritis research and epidemiology (9 papers). Kena A. Swanson is often cited by papers focused on Respiratory viral infections research (22 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Viral gastroenteritis research and epidemiology (9 papers). Kena A. Swanson collaborates with scholars based in United States, Germany and United Kingdom. Kena A. Swanson's co-authors include Philip R. Dormitzer, David Cooper, Alexander Muik, Hui Cai, Uğur Şahin, Mark Cutler, Jing Zou, Pei‐Yong Shi, Xuping Xie and Hongjie Xia and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Kena A. Swanson

34 papers receiving 1.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

2021 383 citations Xuping Xie, Yang Liu et al. Nature Medicine profile →
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

2021 333 citations Alexander Muik, Ann-Kathrin Wallisch et al. Science profile →
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

2022 224 citations Alexander Muik, Ann-Kathrin Wallisch et al. Science profile →
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

2021 212 citations Jianying Liu, Yang Liu et al. Nature profile →
Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons

2025 14 citations Edward E. Walsh, Daniel Eiras et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by Kena A. Swanson

Since Specialization

Citations

This map shows the geographic impact of Kena A. Swanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kena A. Swanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kena A. Swanson more than expected).

Fields of papers citing papers by Kena A. Swanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kena A. Swanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kena A. Swanson. The network helps show where Kena A. Swanson may publish in the future.

Co-authorship network of co-authors of Kena A. Swanson

This figure shows the co-authorship network connecting the top 25 collaborators of Kena A. Swanson. A scholar is included among the top collaborators of Kena A. Swanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kena A. Swanson. Kena A. Swanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa 2025 ·Open Forum Infectious Diseases ·Shabir A. Madhi, Eric A. F. Simões, Nicola P. Klein, Agnieszka Zareba, Philip R. Dormitzer, Daniel A. Scott, Alejandra Gurtman, William C. Gruber, Kathrin U. Jansen, David Cooper, Bing Cai, Beate Schmöele-Thoma, Kena A. Swanson	0
2	Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine 2025 ·Obstetrics and Gynecology ·Shabir A. Madhi, Beate Kampmann, Eric A. F. Simões, Philip Zachariah, Barbara Pahud, David Radley, Uzma Sarwar, Emma Shittu, Conrado J. Llapur, Gonzalo Pérez Marc, Yvonne Maldonado, Alisa Kachikis, Heather J. Zar, Kena A. Swanson, Maria Maddalena Lino, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal	10
3	Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons breakdown → 2025 ·Clinical Infectious Diseases ·Edward E. Walsh, Daniel Eiras, John Woodside, (unknown), Michael A. Patton, Gonzalo Pérez Marc, Conrado J. Llapur, Mika Rämet, Yasushi Fukushima, Nazreen Hussen, José F. Cardona, Tarek Mikati, Agnieszka Zareba, Kumar Ilangovan, Maria Maddalena Lino, Elena Kalinina, Kena A. Swanson, Alejandra Gurtman, Iona Munjal	14
4	P-596. Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results 2025 ·Open Forum Infectious Diseases ·Mark M. Davis, William Towner, Elliot DeHaan, Qin Jiang, Wen Li, Farah Rahman, Michael A. Patton, (unknown), Maria Maddalena Lino, Uzma Sarwar, (unknown), (unknown), (unknown), Kevin Cannon, Elena Kalinina, David Cooper, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Iona Munjal	1
5	Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age 2025 ·Vaccines ·Joel M. Neutel, (unknown), (unknown), Kevin Cannon, (unknown), Ryan Newton, Emily Gomme, Wen Li, Federico Mensa, Özlem Türeci, Uğur Şahin, Kena A. Swanson, Iona Munjal, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin	0
6	A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization 2024 ·Vaccines ·Bing Cai, Yili Chen, (unknown), Beate Schmöele-Thoma, Kenneth Koury, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Kena A. Swanson	0
7	1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults 2023 ·Open Forum Infectious Diseases ·Yasushi Fukushima, José F. Cardona, Agnieszka Zareba, Qin Jiang, Daniel Eiras, Michael A. Patton, Kumar Ilangovan, Elliot DeHaan, Tarek Mikati, Elena Kalinina, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Kena A. Swanson, William C. Gruber, Alejandra Gurtman, Beate Schmöele-Thoma	0
8	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine 2022 ·Nature Communications ·Chaitanya Kurhade, Jing Zou, Hongjie Xia, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‐Yong Shi	41
9	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants 2022 ·npj Vaccines ·Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Uğur Şahin, Xuping Xie, Philip R. Dormitzer, Pei‐Yong Shi	6
10	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 2022 ·Cell Host & Microbe ·Hongjie Xia, Jing Zou, Chaitanya Kurhade, Hui Cai, Qi Yang, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Xuping Xie, Kena A. Swanson, Pei‐Yong Shi	64
11	91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization 2022 ·Open Forum Infectious Diseases ·Eric A. F. Simões, Shabir A. Madhi, Conrado J. Llapur, (unknown), Kena A. Swanson, David Radley, (unknown), Emily Gomme, Daniel A. Scott, Kathrin U. Jansen, William C. Gruber, Alejandra Gurtman	2
12	Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine 2021 ·The Journal of Infectious Diseases ·James T. Peterson, Agnieszka Zareba, David Fitzpatrick, Brandon Essink, Daniel A. Scott, Kena A. Swanson, (unknown), David Radley, David Cooper, Kathrin U. Jansen, Philip R. Dormitzer, William C. Gruber, Alejandra Gurtman	31
13	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera breakdown → 2021 ·Nature Medicine ·Xuping Xie, Yang Liu, Jianying Liu, Xianwen Zhang, Jing Zou, Camila R. Fontes-Garfias, Hongjie Xia, Kena A. Swanson, Mark Cutler, David Cooper, Vineet D. Menachery, Scott C. Weaver, Philip R. Dormitzer, Pei‐Yong Shi	383
14	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants breakdown → 2021 ·Nature ·Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Uğur Şahin, Xuping Xie, Philip R. Dormitzer, Pei‐Yong Shi	212
15	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization 2021 ·npj Vaccines ·Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin R. Tompkins, Mark Cutler, David Cooper, Philip R. Dormitzer, Pei‐Yong Shi	29
16	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera breakdown → 2021 ·Science ·Alexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, Kena A. Swanson, (unknown), Wei Chen, Hui Cai, Daniel Maurus, (unknown), Özlem Türeci, Philip R. Dormitzer, Uğur Şahin	333
17	Anti-infective vaccination in the 21st century—new horizons for personal and public health 2015 ·Current Opinion in Microbiology ·Ingrid L. Scully, Kena A. Swanson, Luke Green, Kathrin U. Jansen, Annaliesa S. Anderson	10
18	Adult vaccination 2014 ·Human Vaccines & Immunotherapeutics ·Kena A. Swanson, H. J. Schmitt, Kathrin U. Jansen, Annaliesa S. Anderson	22
19	The Phenotype and Function of Lung Dendritic Cells 2005 ·Critical Reviews in Immunology ·Tonya J. Webb, Tina L. Sumpter, (unknown), Kena A. Swanson, David S. Wilkes	24
20	Flt3-Ligand, IL-4, GM-CSF, and Adherence-Mediated Isolation of Murine Lung Dendritic Cells: Assessment of Isolation Technique on Phenotype and Function 2004 ·The Journal of Immunology ·Kena A. Swanson, Yan Zheng, Kathleen M. Heidler, (unknown), Tonya J. Webb, David S. Wilkes	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact